Abstract: The KRAS G12D mutation is a prevalent oncogenic driver in several solid tumors, including non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). Historically considered "undruggable" due to the lack of a highly reactive cysteine residue and the absence of deep binding pockets, KRAS G12D has recently been successfully targeted by novel therapeutic strategies. Zoldonrasib (RMC-9805) is a first-in-class, orally bioavailable, mutant-selective, covalent tri-complex inhibitor designed to target the active, GTP-bound "ON" state of KRAS G12D. By acting as a molecular glue that recruits the intracellular chaperone cyclophilin A, Zoldonrasib facilitates covalent modification of the mutant aspartic acid residue, thereby profoundly disrupting downstream oncogenic signaling. Early clinical data from Phase 1/1b trials demonstrate a highly encouraging objective response rate (ORR) of 61% and a disease control rate (DCR) of 89% in patients with KRAS G12D-mutant solid tumors, including NSCLC, alongside a manageable safety profile. This review synthesizes the current literature on Zoldonrasib, detailing its pharmacological activity, unique molecular mechanism, structure-activity relationship, current limitations, and future clinical perspectives in the treatment of KRAS G12D-driven malignancies.
1. Introduction
Mutations in the KRAS oncogene are among the most common drivers of human malignancies, frequently occurring in solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC) [2]. The KRAS protein functions as a molecular switch in signal transduction, alternating between an inactive GDP-bound state and an active GTP-bound state to regulate cell proliferation and survival pathways [1]. Oncogenic mutations, particularly at codon 12, impair intrinsic GTPase activity and GAP-mediated GTP hydrolysis, locking the protein in a constitutively active state [3].
While the development of covalent inhibitors targeting the KRAS G12C mutation (e.g., sotorasib and adagrasib) marked a breakthrough in precision oncology for NSCLC, targeting the KRAS G12D mutation has proven significantly more challenging [2]. The G12D mutation lacks a reactive cysteine residue, rendering traditional covalent inhibition strategies ineffective [2]. However, recent advancements in drug design have led to the development of Zoldonrasib (RMC-9805), an innovative oral inhibitor developed by Revolution Medicines. Zoldonrasib specifically targets the active state of the KRAS G12D mutation and is currently demonstrating significant clinical promise in patients with advanced solid tumors, including NSCLC [2] [3].
2. Pharmacological Activity
Zoldonrasib exhibits potent pharmacological activity both in preclinical models and early-stage clinical trials. In preclinical studies, RMC-9805 effectively inhibited cell proliferation, induced apoptosis, and suppressed RAS pathway activity in vitro [3]. In vivo, it elicited objective tumor regression in multiple mouse xenograft models of KRAS G12D-mutant cancers, including near-complete responses in a majority of tested PDAC models [3].
Clinically, Zoldonrasib is being evaluated in the Phase 1/1b trial NCT06040541 for patients with advanced KRAS G12D-mutant solid tumors [1]. Preliminary data presented at AACR 2025 highlighted highly encouraging antitumor activity, particularly in NSCLC and other solid tumors, achieving an objective response rate (ORR) of 61% and a disease control rate (DCR) of 89% [2]. Furthermore, treatment with Zoldonrasib resulted in early and deep reductions in KRAS G12D circulating tumor DNA (ctDNA) [1].
The safety and tolerability profile of Zoldonrasib has been favorable to date. The most common treatment-related adverse events (TRAEs) are grade 1 or 2, including nausea, diarrhea, vomiting, and rash [1]. Importantly, no grade 4 or 5 adverse events have been reported in the early phases of the study, indicating an acceptable safety margin for this novel therapeutic agent [1].
3. Molecular Mechanism of Action
The molecular mechanism of Zoldonrasib represents a paradigm shift in targeting KRAS mutations. Unlike earlier inhibitors that primarily target the inactive (GDP-bound) "OFF" state of KRAS, Zoldonrasib is a selective RAS(ON) inhibitor that specifically targets the active, GTP-bound state of the KRAS G12D protein [2] [3].
Zoldonrasib functions as a "molecular glue." It first binds to cyclophilin A, an abundant intracellular chaperone protein that does not naturally interact with RAS [2] [3]. The formation of this binary complex induces a conformational change that enables it to bind with high affinity to the GTP-bound KRAS G12D protein. This tri-complex formation brings the inhibitor into precise spatial proximity with the mutant Asp-12 residue, facilitating a covalent modification [2]. By covalently locking the active KRAS G12D protein in this tri-complex, Zoldonrasib sterically blocks the interaction between KRAS and its downstream effector proteins (such as RAF and PI3K), thereby completely disrupting oncogenic RAS signaling cascades [2] [3].
4. Structure-Activity Relationship (SAR)
The structural design of Zoldonrasib overcomes one of the most significant hurdles in KRAS G12D drug discovery: the weak nucleophilicity of the mutant aspartic acid (Asp-12) residue compared to the highly reactive cysteine (Cys-12) found in KRAS G12C mutants [2]. Traditional covalent inhibitors rely on strong nucleophilic attack, which is not feasible with aspartic acid under normal physiological conditions.
To address this, the SAR of Zoldonrasib relies on the tri-complex mechanism. By utilizing cyclophilin A to create a massive neo-protein interface, the drug achieves exceptional binding affinity and selectivity for the KRAS G12D(ON) state [3]. This structural arrangement acts as a strain-release or proximity-driven mechanism that compensates for the poor reactivity of the aspartate carboxylate group, enabling stable covalent acylation of the Asp-12 residue [2]. This highly specific structural requirement ensures that Zoldonrasib selectively inhibits the mutant G12D form while sparing wild-type KRAS and other RAS isoforms, minimizing off-target toxicity [2].
5. Current Limitations
Despite its breakthrough mechanism and promising early clinical data, the development of Zoldonrasib faces several limitations. First, the clinical data are currently restricted to early-phase (Phase 1/1b) trials; therefore, long-term efficacy, durability of response, and comprehensive safety profiles in larger patient populations remain to be fully established [1].
Second, acquired resistance remains a universal challenge for KRAS-targeted therapies. Resistance mechanisms to KRAS inhibitors typically involve secondary mutations within the drug-binding pocket, amplification of the KRAS gene, or the activation of bypass signaling pathways (such as RTK-RAS-MAPK feedback loops or the PI3K/AKT axis) [1] [2]. Furthermore, KRAS G12D mutations are known to foster an immunosuppressive tumor microenvironment and drive metabolic reprogramming, which may contribute to adaptive resistance over time [1] [2].
6. Future Perspectives
The future clinical development of Zoldonrasib in NSCLC and other solid tumors will likely focus on combination strategies to enhance efficacy and prevent the onset of resistance. Preclinical models have already demonstrated that combining KRAS G12D inhibitors like RMC-9805 with immune checkpoint inhibitors can yield synergistic effects, shifting the tumor microenvironment from an immunosuppressive state to an immunostimulatory one characterized by increased CD4+ and CD8+ T cell infiltration [3].
Additionally, clinical trials are currently investigating Zoldonrasib in combination with other targeted agents. For instance, trials are evaluating the co-administration of Zoldonrasib with RMC-6236, a pan-RAS(ON) multi-selective inhibitor, to provide broader blockade of RAS signaling and suppress compensatory pathway reactivation [1]. Combinations with standard-of-care chemotherapies or upstream/downstream inhibitors (e.g., SHP2, SOS1, or PI3K inhibitors) are also critical avenues of ongoing research [1] [2]. As clinical trials (such as NCT06040541 and NCT06445062) progress, the integration of Zoldonrasib into multidimensional, personalized treatment regimens holds the potential to significantly improve survival outcomes for patients with KRAS G12D-mutated NSCLC and other recalcitrant malignancies [1] [2].
